Céline Ollier

598 total citations
10 papers, 394 citations indexed

About

Céline Ollier is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Pharmacology. According to data from OpenAlex, Céline Ollier has authored 10 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 3 papers in Pharmacology and 3 papers in Pharmacology. Recurrent topics in Céline Ollier's work include Antiplatelet Therapy and Cardiovascular Diseases (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Drug Solubulity and Delivery Systems (2 papers). Céline Ollier is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Drug Solubulity and Delivery Systems (2 papers). Céline Ollier collaborates with scholars based in France, United States and United Kingdom. Céline Ollier's co-authors include Olivier Nicolas, Fabrice Hurbin, Dominick J. Angiolillo, M. Dubar, Frank LaCreta, C. Michael Gibson, L. Bergougnan, Laurent Perrin, Shuk Han Cheng and Patricia Zane and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Céline Ollier

10 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Céline Ollier France 8 212 78 74 67 60 10 394
Dorota Danielak Poland 12 252 1.2× 120 1.5× 30 0.4× 48 0.7× 41 0.7× 37 449
B. Kaufmann Germany 14 247 1.2× 86 1.1× 27 0.4× 39 0.6× 68 1.1× 29 650
Margareth Gabrielsson Sweden 7 103 0.5× 55 0.7× 56 0.8× 21 0.3× 86 1.4× 10 348
Regina Sennewald Germany 9 125 0.6× 78 1.0× 48 0.6× 9 0.1× 58 1.0× 13 336
Stefan Blech Germany 6 450 2.1× 126 1.6× 289 3.9× 15 0.2× 81 1.4× 8 771
D. S. Small United States 8 397 1.9× 157 2.0× 103 1.4× 13 0.2× 49 0.8× 12 512
Angela Cheng-Lai United States 13 160 0.8× 117 1.5× 49 0.7× 9 0.1× 22 0.4× 32 398
Bruce S. Gillies United States 8 72 0.3× 133 1.7× 63 0.9× 29 0.4× 240 4.0× 14 660
Jessica Rehmel United States 9 203 1.0× 103 1.3× 46 0.6× 8 0.1× 75 1.3× 15 371
E von Möllendorff United States 9 168 0.8× 61 0.8× 17 0.2× 44 0.7× 88 1.5× 12 430

Countries citing papers authored by Céline Ollier

Since Specialization
Citations

This map shows the geographic impact of Céline Ollier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Ollier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Ollier more than expected).

Fields of papers citing papers by Céline Ollier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Ollier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Ollier. The network helps show where Céline Ollier may publish in the future.

Co-authorship network of co-authors of Céline Ollier

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Ollier. A scholar is included among the top collaborators of Céline Ollier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Ollier. Céline Ollier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Naccarelli, Gerald V., et al.. (2024). Bioavailability of dronedarone tablets administered with or without food in healthy participants. SHILAP Revista de lepidopterología. 45. 100423–100423. 1 indexed citations
2.
Ollier, Céline, et al.. (2020). Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers. Pulmonary Therapy. 6(1). 119–130. 3 indexed citations
3.
Zane, Patricia, Hille Gieschen, Neil Mathias, et al.. (2019). In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development. European Journal of Pharmaceutics and Biopharmaceutics. 142. 222–231. 19 indexed citations
4.
Lennernäs, Hans, Anders Lindahl, A. Van Peer, et al.. (2017). In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context. Molecular Pharmaceutics. 14(4). 1307–1314. 44 indexed citations
5.
Boulenc, Xavier, et al.. (2014). CYP3A4-based drug–drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect. European Journal of Drug Metabolism and Pharmacokinetics. 41(1). 45–54. 33 indexed citations
6.
Klieber, Sylvie, et al.. (2014). Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug. Pharmacology Research & Perspectives. 2(3). e00044–e00044. 20 indexed citations
7.
Zane, Patricia, et al.. (2013). Use of the pentagastrin dog model to explore the food effects on formulations in early drug development. European Journal of Pharmaceutical Sciences. 57. 207–213. 18 indexed citations
8.
Angiolillo, Dominick J., C. Michael Gibson, Shuk Han Cheng, et al.. (2010). Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. Clinical Pharmacology & Therapeutics. 89(1). 65–74. 214 indexed citations
9.
Ollier, Céline, Thierry Duvauchelle, P.M.M. van Haard, et al.. (2002). Absence of Interaction of Fondaparinux Sodium with Aspirin and Piroxicam in Healthy Male Volunteers. Clinical Pharmacokinetics. 41(Supplement 2). 31–37. 21 indexed citations
10.
Mant, Timothy, et al.. (2002). Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy Volunteers. Clinical Pharmacokinetics. 41(Supplement 2). 39–45. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dorota Danielak Breakdown of academic impact, for papers by B. Kaufmann Breakdown of academic impact, for papers by Margareth Gabrielsson Breakdown of academic impact, for papers by Regina Sennewald Breakdown of academic impact, for papers by Stefan Blech Breakdown of academic impact, for papers by D. S. Small Breakdown of academic impact, for papers by Angela Cheng-Lai Breakdown of academic impact, for papers by Bruce S. Gillies Breakdown of academic impact, for papers by Jessica Rehmel Breakdown of academic impact, for papers by E von Möllendorff
Rankless by CCL
2026